Clinical Trial Update: Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602) [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging trial evaluating the efficacy and safety of ciclesonide HFA nasal aerosol in adults and adolescents 12 years and older with seasonal alle…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seasonal Allergic Rhinitis

Drugs mentioned

• ciclesonide HFA nasal aerosol (ciclesonide)

Snippet

Sponsor: AstraZeneca | Conditions: Rhinitis, Allergic, Seasonal | Phase 2 | Status: COMPLETED